US biotech Gilead Sciences (Nasdaq: GILD) has added two names to its senior leadership team, with Kevin Young taking on the chief operating officer role and Martin Silverstein becoming executive vice president for strategy.
Paul Carter, the company’s executive vice president for commercial operations, is to leave Gilead and Mr Young will assume responsibility for the company’s worldwide commercial organization as well as its facilities and operations.
Mr Young was Gilead’s executive vice president of commercial operations from 2004 to 2014, and since then he has been a senior advisor to the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze